Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort

Figures & data

Table 1. Clinical characteristics of the patient cohort^a.

Age at diagnosis
Median (range)	39 (16–63)
Sex
Female	5 (28)
Male	13 (72)
Tumor localization
Spine	4 (22)
Pelvis or sacrum	5 (28)
Upper extremity	8 (44)
Lower extremity	1 (6)
Primary surgery
Curettage	9 (50)
Resection	4 (22)
No surgery	5 (28)
Indication for denosumab
Unresectable primary	5 (28)
Unresectable recurrence	7 (39)
Neoadjuvant/adjuvant	6 (33)

^a Number of patients and percentage (in parentheses) is shown.

Table 2. Surgical procedures performed after neoadjuvant denosumab.

Gender	Age	Tumor localization	Surgical procedure	Less morbid surgery	Neoadjuvant denosumab	Adjuvant denosumab	Recurrence
Female	39	Os trapezium	Complete resection	No	7 months	No	No
Male	40	Proximal humerus	Curettage and cementing	Yes	12 months	1 month	No
Male	63	Os hamatum	Partial resection	No	11 months	6 months	Yes
Female	37	Distal tibial bone	Curettage and cementing	No	7 months	7 months	Yes
Male	25	Os pubis and os ileum	Curettage and bone grafting	Yes	11 months	6 months	Yes
Male	16	Distal radial bone	Curettage and bone grafting	Yes	7 months	5 months	Yes

Figure 1. Coronal 18F-FDG PET/CT images from a patient with a tumor in the distal tibial bone at baseline (A) and at first evaluation after 4 weeks (B). (C) Boxplot showing SUV_max at baseline and first evaluation for all patients.